PURPOSE: More effective intravesical agents are required to limit the recurrence and progression of superficial bladder cancer. This study assessed the ability of copper-67 (67 Cu)-C595 murine ...
Ferring Pharmaceuticals today announced a new real-world case series demonstrating that re-induction with ADSTILADRIN ® (nadofaragene firadenovec-vncg) resulted in complete responses (CR) in ...
Pediatric neuropathic bladder dysfunction can cause irreversible renal damage and urinary incontinence. Etiologically, it is usually the consequence of a congenital neural tube defect. The majority of ...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the first patient in the United States with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder ...
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced data from intravesical instillation of enfortumab vedotin (EV) in a non-muscle invasive bladder cancer (NMIBC) preclinical ...
SurvivorNet on MSN
Inlexzo: A new option for bladder cancer patients when BCG immunotherapy stops working
If you or a loved one has been diagnosed with BCG-unresponsive non-muscle invasive bladder cancer and are exploring your options, talk to a urologist or genitourinary oncologist about whether Inlexzo ...
Patients with multiple sclerosis (MS) often have lower urinary tract symptoms, which are usually treated with clean intermittent catheterization and oral antimuscarinic drugs; however, these agents ...
First and only drug releasing system to provide extended local delivery of a cancer medication into the bladder, with 82 percent of patients achieving complete response without the need for ...
CHICAGO -- An investigational intravesical delivery system designed to provide sustained local release of gemcitabine into the bladder produced high rates of complete response (CR) in ...
ImmunityBio Inc. IBRX on Monday said it entered an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory ...
Five issued U.S. patents cover the combination of ImmunityBio’s IL-15 receptor agonist (NAI) with Bacillus Calmette-Guérin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results